Background: Type 2 diabetes mellitus (T2DM) is a complicated and multifaceted metabolic disease defined by insulin resistance, dyslipidemia, oxidative stress, and β-cell dysfunction. Tirzepatide (TZP), a dual GIP and GLP-1 receptor agonist, offers potent glucose-lowering and weight-loss. Objective: To assess the effect of different doses of TZP on lipid profile, SOD activity, and histopathological changes of the pancreas in a high-fat diet and streptozotocin-induced T2DM. Methods: Thirty male Wistar rats were divided into five groups (n=6): Group I, control group, Groups II-V were induced with diabetes by feeding with a high-fat diet for six weeks with a single injection of streptozocin (35 mg/kg). Groups III- V were treated with TZP at three doses: low, medium, and high (0.44, 0.88, and 1.32 mg/kg) subcutaneously once weekly for 4 weeks. Blood and pancreas samples were then collected for biochemical and histopathological analyses. Result: The results showed that all doses of TZP-treated groups significantly lowered (p<0.0001) cholesterol, TG, LDL, and VLDL, and increased SOD and HDL levels in a dose-response manner compared to the T2DM rats. while all doses of the TZP-treated groups revealed pronounced improvements in pancreatic architecture, especially at the higher doses. Conclusion: Treatment of T2DM rats with TZP ameliorated their lipid profile, improving pancreatic architecture and augmenting antioxidant activity.
No takes yet. Share an insight, caveat, or question.
Fakhir et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: